SEARCH

SEARCH BY CITATION

References

  • Adam, K., Allen, S., Carruthers-Jones, I. & Spence, M. (1976). Mesoridazine and human sleep. British Journal of Clinical Pharmacology, 3, 157163.
  • Ahmad, M. & Prakash, K. (2010). Reversible hyperkinetic movement disorder associated with quetiapine withdrawal. Movement Disorders, 25 (9), 13081309.
  • Ahmed, S., Chengappa, K., Naidu, V., Baker, R., Parepally, H. & Schooler, N. (1998). Clozapine withdrawal-emergent dystonias and dyskinesias: A case series. Journal of Clinical Psychiatry, 59 (9), 472477.
  • Amore, M. & Zazzeri, N. (1995). Neuroleptic malignant syndrome after neuroleptic discontinuation. Progress in Neuropsychopharmacology and Biological Psychiatry, 19 (8), 13231334.
  • Anand, V. & Dewan, M. (1996). Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Annals of Clinical Psychiatry, 8 (3), 179182.
  • Aparasu, R. R. & Bhatara, V. (2005). Antipsychotic prescribing trends among youths, 1997–2002. Psychiatric Services, 56 (8), 904.
  • Ballard, C., Hanney, M. L., Theodoulou, M. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomized placebo-controlled trial. The Lancet Neurology, 8 (2), 151157.
  • Bastiampillai, T., Forooziya, F. & Dhillon, R. (2009). Clozapine-withdrawal catatonia. Australia and New Zealand Journal of Psychiatry, 43 (3), 283284.
  • Botvinik, L., Ng, C. & Schweitzer, I. (2004). Audit of antipsychotic prescribing in a private psychiatric hospital. Australasian Psychiatry, 12 (3), 227233.
  • Brooks, G. W. (1959). Withdrawal from neuroleptic drugs. American Journal of Psychiatry, 115 (10), 931932.
  • Chemerinski, E., Ho, B. C., Flaum, M., Arndt, S., Fleming, F. & Andreasen, N. C. (2002). Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Comprehensive Psychiatry, 43 (5), 393396.
  • Chouinard, G. & Chouinard, V. A. (2008). Atypical antipsychotics: CATIE Study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics, 77 (2), 6977.
  • Chouinard, G. & Jones, B. D. (1980). Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. American Journal of Psychiatry, 137 (1), 1621.
  • Chue, P., Remington, G. & Kapala, L. (2004). Switching atypical antipsychotics: A review. Acta Neuropsychiatrica, 16, 301313.
  • Cooper, W. O., Arbogast, P. G., Ding, H., Hickson, G. B., Fuchs, D. C. & Ray, W. A. (2006). Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatrics, 6 (2), 7983.
  • Corrigan, F. & Coulter, F. (1988). Neuroleptic malignant syndrome: Amitriptyline, and thioridazine. Biological Psychiatry, 23, 320321.
  • Dixon, L., Thaker, G., Conley, R., Ross, D., Cascella, N. & Tamminga, C. (1993). Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophrenia Research, 10, 267271.
  • Duxbury, J., Wright, K., Bradley, D. & Barnes, P. (2010). Administration of medication in the acute mental health ward: Perspective of nurses and patients. International Journal of Mental Health Nursing, 19, 5361.
  • Edward, K., Munro, I., Robins, A. & Welch, A. (2011). Mental Health Nursing: Dimensions of Praxis. South Melbourne: Oxford University press.
  • Ehrt, U., Fritze, F. & Aarsland, D. (2005). Respiratory dyskinesia as discontinuation effect of risperidone. Journal of Clinical Psychopharmacology, 25 (6), 609.
  • Elder, R., Evans, K. & Nizette, D. (2009). Psychiatric and Mental Health Nursing, 2nd edn. Sydney: Elsvier.
  • Faheem, A., Brightwell, D., Burton, G. & Strauss, A. (1982). Respiratory dyskinesia and dysarthria from prolonged neuroleptic use: Tardive dyskinesia? American Journal of Psychiatry, 4, 517518.
  • Gallant, D. M., Edwards, C. G., Bishop, M. P. & Galbraith, G. C. (1964). Withdrawal symptoms after abrupt cessation of antipsychotic compounds: Clinical confirmation in chronic schizophrenics. Clinical Notes, 491493.
  • Gardos, G. & Cole, J. O. (1976). Maintenance antipsychotic therapy: Is the cure worse than the disease? American Journal of Psychiatry, 133 (1), 3236.
  • Gardos, G., Cole, J. O. & Tarsy, D. (1978). Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry, 135 (11), 13211324.
  • Goudie, A., Smith, J., Robertson, A. & Cavanagh, C. (1999). Clozapine as a drug of dependence. Psychopharmacology, 142, 369374.
  • Goudie, A., Cole, J. & Sumnall, H. (2007). Olanzapine withdrawal/discontinuation-induced hyperthermia in rats. Progress in Neuropsychopharmacology and Biological Psychiatry, 31, 15001503.
  • Goudie, A. J. (2000). What is the clinical significance of the discontinuation syndrome seen with clozapine? Journal of Psychopharmacology, 14 (2), 188190.
  • Greenberg, L. M. & Roth, S. (1966). Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry, 123 (2), 221226.
  • Grimshaw, J. & Russell, I. (1993). Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations. Lancet, 342 (8883), 13171322.
  • Harris, N., Lovell, K., Day, J. & Roberts, C. (2009). An evaluation of a medication management training program for community mental health professionals; service user level outcomes: A cluster randomized controlled trial. International Journal of Nursing Studies, 46 (5), 645652.
  • Healy, D. & Tranter, R. (1999). Pharmacological stress diathesis syndromes. Journal of Psychopharmacology, 13 (3), 287290.
  • Hermann, R. C., Yang, D., Ettner, S. L., Marcus, S. C., Yoon, C. & Abraham, M. (2002). Prescription of antipsychotic drugs by office-based physicians in the United States, 1989–1997. Psychiatric Services, 53 (4), 425430.
  • Hollister, L. E., Eikenberry, D. T. & Raffel, S. (1960). Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. The American Review of Respiratory Disease, 81, 562566.
  • Howland, R. H. (2010). Potential adverse effects of discontinuing psychotropic drugs part 3: Antipsychotic, dopaminergic, and mood-stabilizing drugs. Journal of Psychosocial Nursing, 48 (8), 1114.
  • Hungerford, C., Clancy, R., Hodgson, D., Jones, T. & Harrison, A. (2012). Mental Health Care: An Introduction for Health Professionals. Milton, Qld: Wiley.
  • Judah, L. N., Josephs, Z. M. & Murphree, O. D. (1961). Results of simultaneous abrupt withdrawal of ataraxics in 500 chronic psychotic patients. The American Journal of Psychiatry, 118, 156158.
  • Jus, K., Jus, A., Beland, C. et al. (1976). Sleep analysis during drug-free weekends in chronic schizophrenic patients. Biological Psychiatry, 11 (6), 709718.
  • Kasckow, J., Dolor, R. & Lipper, S. (1990). Delayed onset of neuroleptic malignant syndrome after discontinuation of thioridazine. Journal of Clinical Psychopharmacology, 10 (2), 146.
  • Kaye, J. A., Bradbury, B. D. & Jick, H. (2003). Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: A population-based observational study. British Journal of Clinical Pharmacology, 56 (5), 569575.
  • Kent, T. A. & Wilber, R. D. (1982). Reserpine withdrawal psychosis: The possible role of denervation supersensitivity of receptors. Journal of Nervous Mental Disorders, 170 (8), 502504.
  • Kim, D. R. & Staab, J. P. (2005). Quetiapine discontinuation syndrome. American Journal of Psychiatry, 162 (5), 1020.
  • Kohen, I. & Kremen, N. (2009). A case report of quetiapine withdrawal in a geriatric patient. The World Journal of Biological Psychiatry, 10 (4), 985986.
  • Komatsu, S., Kirino, E., Inoue, Y. & Arai, H. (2005). Risperidone withdrawal-related respiratory dyskinesia: A case diagnosed by spirography and fibroscopy. Clinical Neuropharmacology, 28, 9093.
  • Kruk, J., Sachdev, P. & Singh, S. (1995). Neuroleptic-induced respiratory dyskinesia. Journal of Neuropsychiatry and Clinical Neuroscience, 7, 223229.
  • Lacoursiere, R., Spohn, H. & Thompson, K. (1976). Medical effects of abrupt neuroleptic withdrawal. Comprehensive Psychiatry, 17 (2), 285294.
  • Laugharne, J., Davies, A., Arcelus, J. & Bouman, W. P. (2004). Informing patients about tardive dyskinesia: A survey of clinicians' attitudes in three countries. International Journal of Law Psychiatry, 27 (1), 101108.
  • Lee, J. W. & Robertson, S. (1997). Clozapine withdrawal catatonia and neuroleptic malignant syndrome: A case report. Annals of Clinical Psychiatry, 9 (3), 165169.
  • Lehmann, P. (2002). Coming off Psychiatric Drugs: Successful Withdrawal from Neuroleptics, Antidepressants, Lithium, Carbemazepine and Tranquilizers. Shrewsbury: Peter Lehmann Publishing.
  • Lieberman, J., Stroup, T., McEvoy, J. et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353 (12), 12091223.
  • Llorca, P. M., Vaiva, G. & Lancon, C. (2001). Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Canadian Journal of Psychiatry, 46 (1), 8788.
  • Margetic, B. & Aukst-Margetic, B. (2005). Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Progress in Neuropsychopharmacology and Biological Psychiatry, 29 (1), 145147.
  • May, D. C., Morris, S. W., Stewart, R. M., Fenton, B. J. & Gaffney, F. A. (1983). Neuroleptic malignant syndrome: Response to dantrolene sodium. Annals Internal Medicine, 98 (2), 183184.
  • McGorry, P. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39 (1–2), 130.
  • McIntosh, A., Conlon, L., Lawrie, S. & Stanfield, A. (2010). Compliance therapy for schizophrenia. Cochrane Database of Systematic Reviews, (3) Art. No.: CD003442. DOI: 10.1002/14651858.CD003442.pub2.
  • Mendhekar, D. N. & Inamdar, A. (2010). Withdrawal-emergent respiratory dyskinesia with risperidone treated with clozapine. Journal of Neuropsychiatry and Clinical Neuroscience, 22 (2), E24.
  • Michaelides, C., Thakore-James, M. & Durso, R. (2005). Reversible withdrawal dyskinesia associated with quetiapine. Movement Disorders, 20 (6), 769770.
  • Mind (1998). Psychiatric Drugs: Users' Experiences and Current Policy and Practice. London: Mind.
  • Mitchell, J. E. (1981). Discontinuation of antipsychotic drug therapy. Psychosomatics, 22 (3), 241245.
  • Mohr, W. (2006). Psychiatric-mental Health Nursing, 6th edn. Sydney: Lippincott Williams & Wilkins.
  • Moncrief, J. (2006a). Why is it so difficult to stop psychiatric drug treatment? It may be nothing to with the original problem. Medical Hypotheses, 67 (3), 517523.
  • Moncrieff, J. (2006b). Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114 (1), 313.
  • National Schizophrenia Fellowship (2000). A Question of Choice. London: National Schizophrenia Fellowship.
  • Nayuda, S. & Scneftner, W. (2000). Case report of withdrawal syndrome after olanzapine discontinuation. Journal of Clinical Psychopharmacology, 20 (4), 489490.
  • Nishimura, K., Tsuka, M. & Horikawa, N. (2001). Withdrawal-emergent rabbit syndrome during dose reduction of risperidone. European Neuropsychopharmacology, 11 (4), 323324.
  • Nofzinger, E., Van Kammen, D., Gilbertson, M. W., Gurklis, J. & Peters, J. (1993). Electroencephalogrphic sleep in clinically stable schizophrenic patients: Two weeks versus six-weeks neuroleptic-free. Biological Psychiatry, 33, 829835.
  • Olofinjana, B. & Taylor, D. (2005). Antipsychotic drugs- information and choice: A patient survey. Psychiatric Bulletin, 29, 369371.
  • Oral, E. T., Altinbas, K. & Demirkiran, S. (2006). Sudden akathisia after a ziprasidone dose reduction. American Journal of Psychiatry, 163 (3), 546.
  • Parsa, M. A., al-Lahham, Y. H., Ramirez, L. F. & Meltzer, H. Y. (1993). Prolonged psychotic relapse after abrupt clozapine withdrawal. Journal of Clinical Psychopharmacology, 13 (2), 154155.
  • Quirk, A., Chaplin, R., Lelliott, P. & Seale, C. (2009). The negotiation of prescribing decisions: Some good practice issues. In: N. Harris , J. Baker & R. Gray (Eds). Medicines Management in Mental Health Care. (pp. 133144). Singapore: Wiley-Blackwell.
  • Rani, F., Murray, M. L., Byrne, P. J. & Wong, I. C. K. (2008). Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics, 121 (5), 10021009.
  • Read, J. (2009). Psychiatric Drugs: Key Issues and Service User Perspectives. New York: Palgrave Macmillan.
  • Ruths, S., Straand, J., Nygaard, H., Bjorvatn, B. & Pallese, S. (2004). Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: A randomized, placebo-controlled, double-blinded study: The Bergen district nursing home study. Journal of the American Geriatric Society, 52 (10), 17371743.
  • SAMH (2004). All you need to know? Scottish survey of peoples experiences of psychiatric drugs. [Cited 14 July 2009]. Available from: URL: http://www.psychminded.co.uk/news/news2004/april04/allyouneedtoknow.pdf
  • Schirm, E., Tobi, H., Zito, J. M. & Jong-van den Berg, L. T. (2001). Psychotropic medication in children: A study from the Netherlands. Pediatrics, 108 (2), E25.
  • Seale, C., Chaplin, R., Lelliott, P. & Quirk, A. (2006). Sharing decisions in consultations involving anti-psychotic medication: A qualitative study of psychiatrists' experiences. Social Science and Medicine, 62, 28612873.
  • Seppälä, N., Kovio, C. & Leinonen, E. (2005). Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. Central Nervous System Drugs, 19 (12), 10491055.
  • Staedt, J., Stoppe, G., Hajak, G. & Ruther, E. (1996). Rebound insomnia after abrupt clozapine withdrawal. Eur Arch Psychiatry Clin Neurosci, 246, 7982.
  • Stanford, J. & Fowler, S. (1997). Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness. Psychopharmacology, 132, 408414.
  • Stonecipher, A., Galang, R. & Black, J. (2006). Psychotropic discontinuation symptoms: A case of withdrawal neuroleptic malignant syndrome. General Hospital Psychiatry, 28 (6), 541543.
  • Thaker, G. K., Wagman, A. M., Kirkpatrick, B. & Tamminga, C. A. (1989). Alterations in sleep polygraphy after neuroleptic withdrawal: A putative supersensitive dopaminergic mechanism. Biological Psychiatry, 25 (1), 7586.
  • Thanasan, S. (2010). clozapine withdrawal catatonia or lethal catatonia in a schizoaffective patient with a family history of parkinsons disease. African Journal of Psychiatry, 13, 402404.
  • Thurstone, C. & Alahi, P. (2000). A possible case of quetiapine withdrawal syndrome. Journal of Clinical Psychiatry, 61 (8), 602603.
  • Tollefson, G., Dellva, M., Mattler, C., Kane, J., Wirshing, D. & Kinon, B. (1999). Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. Journal of Clinical Psychopharmacology, 19 (5), 435443.
  • Urbano, M., Spiegel, D. & Rai, A. (2007). Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders. Journal of Clinical Psychopharmacology, 27 (6), 705707.
  • Verdoux, H., Tournier, M. & Bégaud, B. (2010). Antipsychotic prescribing trends: A review of pharmaco-epidemiological studies. Acta Psychiatrica Scandanavica, 121 (1), 410.
  • Verghese, C., DeLeon, J., Nair, C. & Simpson, G. M. (1996). Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biological Psychiatry, 39, 135138.
  • Wadekar, M. & Syed, S. (2010). Clozapine withdrawal catatonia. Psychosomatics, 51 (4), 355355e2.
  • Wahlbeck, K., Tuunainen, A., Ahokas, A. & Leucht, S. (2001). Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl), 155 (3), 230233.
  • Williams, C. L., Johnstone, B., Kesterson, M., Javor, K. & Schmetzer, A. (1999). Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care, 37 (4), 8186.
  • Yeh, A. W. C., Lee, J. W. Y., Cheng, T. C., Wen, J. K. & Chen, W. H. (2004). Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: A case report. Clinical Neuropharmacology, 27 (5), 216218.
  • Zesiewicz, T. A., Sujatha, S. & Hauser, R. A. (2002). Clozapine withdrawal symptoms in a Parkinson's disease patient. Mov Disord, 17, 13651367.